Drugs / Palonosetron
Palonosetron
also known as
Palonosetron Hydrochloride · Aloxi · PALO · Palonosetron HCl · palonosetron hydrochloride injection · Aloxi (palonosetron) · NSC-743769 · Palonocetron hydrochloride · +9 more
Other / unclassified targets HTR3A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | POSFREA | — | 2025-04-16 | fda.gov ↗ |
| Label expansion | US (FDA) | PALONOSETRON HYDROCHLORIDE | — | 2018-12-06 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | ALOXI | — | 2007-08-30 – 2014-05-27 | fda.gov ↗ |
| Approved | EU (EMA) | Aloxi | — | 2005-03-22 | europa.eu ↗ |
| Approved | US (FDA) | ALOXI | — | 2003-07-25 | fda.gov ↗ |
Trials 73 · started per year
today
US approved 2003
EU approved 2005
1
9
2
3
5
2
7
3
1
1
6
2
4
5
1
5
4
3
2
2
4
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07662200 | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06427681 | May → Sep 2024 | — | Zhuhai Beihai Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06840769 | Jun → Oct 2023 | — | Helsinn Healthcare SA | Terminated | No outcome recorded |
| Phase 1 | NCT05465681 | Aug 2022 → Jan 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01046240 | Oct 2009 → Nov 2010 | — | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT07692451 | Jul 2026 → Jul 2027 expected | chemotherapy-induced toxicity | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06904235 | Jul 2025 → Oct 2027 expected | chemotherapy-induced toxicity | Helsinn Healthcare SA | Recruiting | No outcome recorded |
| Phase 2 | NCT05315999 | May 2022 → Dec 2024 | — | Gerhild Becker | Completed | No outcome recorded |
| Phase 2 | NCT04669132 | Dec 2020 → Dec 2021 | chemotherapy-induced toxicity | Instituto Brasileiro de Controle do Cancer | Completed | No outcome recorded |
| Phase 2 | NCT05202275 | Dec 2020 → Dec 2022 | head and neck squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04592198 | Oct 2020 → Mar 2021 | chemotherapy-induced toxicity | Xiamen LP Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03386617 | Feb 2018 → Dec 2027 expected | breast cancer | Chinese University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03204279 | Aug 2017 → Sep 2019 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT03097588 | Apr 2017 → Feb 2020 | cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03008213 | Jan 2017 → Jan 2018 | chemotherapy-induced toxicity | Joseph Ma | Terminated | No outcome recorded |
| Phase 2 | NCT02388750 | Apr 2015 → Aug 2017 | — | Dr. Edward Chow | Completed | No outcome recorded |
| Phase 2 | NCT01370408 | Feb 2012 → Mar 2016 | chemotherapy-induced toxicity | Northside Hospital, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01909856 | Oct 2011 → Apr 2014 | cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00982995 | Nov 2010 → May 2013 | — | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01054456 | Oct 2009 → Dec 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00903396 | Sep 2009 → Jan 2011 | anus cancer, appendix carcinoma, carcinoid tumor, extrahepatic bile duct carcinoma +5 | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT00900757 | Aug 2009 → Dec 2012 | malignant glioma | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT00636805 | May 2008 → Jan 2013 | brain cancer | Duke University | Terminated | No outcome recorded |
| Phase 2 | NCT00600353 | Oct 2007 → Jan 2010 | plasma cell myeloma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01018758 | Jul 2006 → Jul 2008 | chemotherapy-induced toxicity, non-Hodgkin lymphoma | Gruppo Italiano Studio Linfomi | Completed | No outcome recorded |
| Phase 2 | NCT00381862 | Jun 2006 → Mar 2008 | colorectal cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00503386 | Apr → Oct 2006 | — | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00306735 | Mar 2006 → Dec 2007 | plasma cell myeloma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01031498 | Sep 2005 → Sep 2009 | acute myeloid leukemia, chemotherapy-induced toxicity | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00666783 | — | chemotherapy-induced toxicity | Xijing Hospital | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03040726 | May 2017 → Feb 2022 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT03606369 | Nov 2015 → Jul 2018 | breast neoplasm | National Cancer Institute of Mexico | Unknown | No outcome recorded |
| Phase 314 trials | ||||||
| Phase 3 | NCT05199818 | Mar 2022 → Sep 2023 | chemotherapy-induced toxicity | Xiamen LP Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT03817970 | Nov 2019 → Sep 2027 expected | cisplatin toxicity | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04060771 | Aug 2018 → Nov 2019 | strabismus | Fluminense Federal University | Unknown | No outcome recorded |
| Phase 3 | NCT03403712 | Mar → Sep 2018 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT02517021 | Nov 2015 → Aug 2016 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT02557035 | Oct 2015 → Mar 2016 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01568268 | Jan → Jun 2012 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01442376 | Sep 2011 → Oct 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01363479 | Jul 2011 → Nov 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01395901 | Jun 2011 → Mar 2012 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01339260 | Apr 2011 → Nov 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT00828295 | Aug → Dec 2008 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT00475085 | Dec 2006 → Dec 2012 | — | Joseph Roscoe | Completed | No outcome recorded |
| Phase 3 | NCT00359567 | Jul 2006 → May 2007 | chemotherapy-induced toxicity | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 416 trials | ||||||
| Phase 4 | NCT07482891 | Mar → Oct 2026 expected | chemotherapy-induced toxicity | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06540885 | Jan 2025 → Jul 2026 overdue | idiopathic scoliosis | University of Malaya | Recruiting | No outcome recorded |
| Phase 4 | NCT06726291 | Feb 2024 → Dec 2025 overdue | endometrial cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting | No outcome recorded |
| Phase 4 | NCT05841849 | Jul 2023 → Jul 2028 expected | breast cancer, chemotherapy-induced toxicity | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05956899 | Jun 2023 → Mar 2024 | idiopathic scoliosis | University of Malaya | Completed | No outcome recorded |
| Phase 4 | NCT03831633 | Sep 2018 → Jul 2019 | — | VIFORFRANCE | Unknown | No outcome recorded |
| Phase 4 | NCT06043336 | May 2018 → May 2019 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 4 | NCT02941913 | Oct 2016 → Feb 2018 | — | Brazilian National Cancer Institute | Completed | No outcome recorded |
| Phase 4 | NCT02809378 | Jun 2016 → Apr 2017 | — | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02541019 | Oct 2015 → Jan 2017 | — | Bonsucesso Federal Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02468323 | Oct 2015 → Feb 2017 | — | Hospital de Base | Completed | No outcome recorded |
| Phase 4 | NCT01481831 | Jul 2011 → Aug 2012 | chemotherapy-induced toxicity, neoplasm | Shanghai Changzheng Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02635828 | Oct 2009 → May 2011 | — | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT00684463 | Apr 2007 → Feb 2008 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00415103 | Nov 2006 → Sep 2009 | leukemia, lymphoma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00687011 | Oct 2006 → Oct 2008 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07442890 | Apr 2026 → Apr 2028 expected | lung cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05690802 | May 2022 → May 2027 expected | — | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT04563260 | Oct 2020 → Mar 2021 | gallbladder disorder | Ajou University School of Medicine | Completed | No outcome recorded |
| — | NCT04507711 | Sep 2020 → Nov 2023 | blood coagulation disease | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| — | NCT02597907 | Jul 2014 → May 2015 | — | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT01952626 | Apr 2013 → Jun 2014 | poisoning | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT01650961 | Jul → Dec 2012 | — | Seoul National University Hospital | Completed | No outcome recorded |
| — | NCT01640340 | Jan → Aug 2011 | cancer | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT01169805 | Aug 2010 → Jun 2011 | non-congenital cyst of kidney | Yonsei University | Completed | No outcome recorded |
| — | NCT00661674 | Apr → Aug 2008 | substance-related disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00343863 | Jan 2006 → Dec 2010 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
Also used as a comparator or background therapy in 55 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02650479 Background | Jan → Apr 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00412425 Comparator | Nov 2006 → May 2009 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07709897 Background | Jul → Dec 2026 expected | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07617246 Comparator | Nov 2025 → Jan 2027 expected | esophageal cancer, lung cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT04308837 Background | Dec 2018 → Aug 2025 | gastric cancer | Icahn School of Medicine at Mount Sinai | Unknown | No outcome recorded |
| Phase 2 | NCT03960151 Background | May 2018 → May 2021 | germ cell tumor | Costantine Albany | Withdrawn | No outcome recorded |
| Phase 2 | NCT02445872 Background | Dec 2015 → May 2016 | chemotherapy-induced toxicity, lung cancer | Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT02290470 Background | Apr 2014 → Nov 2015 | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Unknown | No outcome recorded |
| Phase 2 | NCT01736917 Background | Jan 2013 → Mar 2015 | chemotherapy-induced toxicity | Lawrence Einhorn | Completed | No outcome recorded |
| Phase 2 | NCT02205164 Comparator | Oct 2011 → Aug 2014 | chemotherapy-induced toxicity | Associazione Salentina Angela Serra | Unknown | No outcome recorded |
| Phase 2 | NCT00967499 Comparator | Jul → Dec 2009 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00895245 Background | Feb 2009 → Sep 2010 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, lip and oral cavity squamous cell carcinoma, nasopharyngeal squamous cell carcinoma +1 | University of Washington | Terminated | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT07081256 Comparator | Jan → Aug 2025 | chemotherapy-induced toxicity | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06554184 Comparator | Sep 2024 → Jul 2025 | chemotherapy-induced toxicity | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06331520 Background | May 2024 → Aug 2025 | chemotherapy-induced toxicity | Fudan University | Completed | No outcome recorded |
| Phase 3 | NCT06200168 Background | Jan 2024 → Oct 2026 expected | — | Jiuda Zhao | Recruiting | No outcome recorded |
| Phase 3 | NCT05509634 Comparator | Sep 2022 → Jun 2023 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05439798 Comparator | Jun 2022 → Apr 2023 | — | Selcuk University | Unknown | No outcome recorded |
| Phase 3 | NCT04912271 Comparator | Jun 2021 → Jun 2022 | chemotherapy-induced toxicity | Fudan University | Unknown | No outcome recorded |
| Phase 3 | NCT04853147 Background | Apr 2021 → Apr 2022 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT04437017 Comparator | Feb 2020 → May 2022 | chemotherapy-induced toxicity | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT03578081 Background | Nov 2018 → Nov 2021 | cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT02933099 Comparator | Oct 2016 → Apr 2018 | chemotherapy-induced toxicity | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 3 | NCT03674294 Background | Aug 2015 → Mar 2020 | chemotherapy-induced toxicity, digestive system neoplasm | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02484911 Background | May 2015 → Sep 2016 | chemotherapy-induced toxicity | First Affiliated Hospital of Harbin Medical University | Completed | No outcome recorded |
| Phase 3 | NCT02116530 Background | Aug 2014 → Apr 2015 | cancer of unknown primary site, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT02203253 Comparator | Jul 2014 → Jul 2016 | neoplasm | China Medical University, China | Completed | No outcome recorded |
| Phase 3 | NCT02135510 Comparator | Jun 2013 → Mar 2019 | cancer | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 3 | NCT01376297 Comparator | Jul 2011 → Sep 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01088022 Background | Apr 2010 → Mar 2013 | — | Azienda Ospedaliera di Perugia | Unknown | No outcome recorded |
| Phase 3 | NCT00553059 Background | May 2008 → Aug 2014 | cancer of unknown primary site, chemotherapy-induced toxicity | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00343460 Comparator | Jun 2006 → Sep 2008 | cancer of unknown primary site | Heron Therapeutics | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07637968 Background | Jun 2026 → Jan 2027 expected | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07254416 Background | Dec 2025 → Dec 2026 expected | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04817189 Comparator | Feb 2021 → Jul 2024 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 4 | NCT04576390 Comparator | Oct 2020 → Apr 2021 | — | Theodor Bilharz Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT03586817 Comparator | Mar 2019 | — | Bonsucesso Federal Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02532634 Comparator | Aug 2015 → May 2018 | cancer | Kangdong Sacred Heart Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02480088 Comparator | Sep 2014 → Mar 2015 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02114463 Background | Mar 2014 → Aug 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 4 | NCT02094339 Background | Mar 2014 → Jun 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 4 | NCT01872494 Comparator | May 2013 → Feb 2014 | — | Guangzhou General Hospital of Guangzhou Military Command | Completed | No outcome recorded |
| Phase 4 | NCT00952133 Comparator | Jul 2009 → Jul 2010 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07480785 Background | Jan 2026 → Oct 2027 expected | gallstones, leiomyoma, ovarian neoplasm | Zhejiang University | Recruiting | No outcome recorded |
| — | NCT03601871 Background | Jul 2018 → Jun 2020 | chemotherapy-induced toxicity | Yunpeng Liu | Unknown | No outcome recorded |
| — | NCT03933605 Comparator | Jul 2017 → Feb 2019 | — | Yeungnam University College of Medicine | Completed | No outcome recorded |
| — | NCT02970643 Background | Jul 2016 → Sep 2017 | chemotherapy-induced toxicity | Hee Jun Kim | Unknown | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02744508 Comparator | Jul 2015 → Mar 2017 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01482468 Comparator | Mar → Jul 2012 | — | Incheon St.Mary's Hospital | Unknown | No outcome recorded |
| — | NCT01843868 Background | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded |
| — | NCT01478165 Comparator | Sep → Nov 2011 | — | Incheon St.Mary's Hospital | Completed | No outcome recorded |
| — | NCT01825733 Comparator | Aug 2011 → Jul 2012 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01476280 Comparator | May → Aug 2011 | — | Incheon St.Mary's Hospital | Completed | No outcome recorded |
| — | NCT00410488 Comparator | Dec 2006 → Jun 2011 | sarcoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-03-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces the Launch of a Generic Version of ALOXI® in the United States tevapharm.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 133 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Palonosetrón | “BACKGROUND: This phase I trial aimed to assess the pharmacokinetics (PK), safety, and preliminary efficacy of a single dose of HR20013 (mixed formulation of fosrolapitant and...” PMID 40866861 ↗ Aug 2025122“Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).” PMID 22733373 ↗ Jun 2012 “Olanzapine 2.5 mg per day orally on days 1 through 4 + fosaprepitant 150 mg intravenous (IV) or aprepitant injectable emulsion 130 mg IV + palonosetron 0.25 mg” NCT06200168 ↗ “Dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure.” NCT07480785 ↗ “Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3” NCT03601871 ↗ “The registered product Akynzeo® (235 mg fosnetupitant/0.25 mg palonosetron) solution for intravenous injection” NCT06840769 ↗ “flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02114463 ↗ “flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02094339 ↗ “Oral Fixed-dose Combination of 300 mg Netupitant and 0.50 mg Palonosetron” NCT03386617 ↗ “0.25 mg palonosetron intravenously 30 minutes (±1 minute)” NCT06427681 ↗ “Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.” NCT01736917 ↗ “Palonosetrón: 0.25 mg iv every 48 hours, starting day 1” NCT00415103 ↗ “containing 300 mg netupitant and 0.5 mg palonosetron).” NCT03831633 ↗ “Palonosetron 0.56 mg, once daily, on chemotherapy day;” NCT04669132 ↗ “Palonosetron: 0.25 mg d1 intravenous” NCT04437017 ↗ “palonosetron” NCT01843868 ↗ “Palonosetron” NCT05202275 ↗ |
| Known as | Aloxi | “Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle” NCT01339260 ↗6“single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug)” NCT01363479 ↗ “.075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.” NCT00952133 ↗ “Palonosetron (Aloxi) and Dexamethasone” NCT00636805 ↗ “IV palonosetron 0.25 Mg (ALOXI®)” NCT04592198 ↗ “Palonosetron Injection [Aloxi]” NCT04563260 ↗ “Aloxi (Palonosetron HCl)” NCT00306735 ↗ |
| Known as | Aloxi (palonosetron) | “Aloxi (palonosetron)” NCT01568268 ↗ |
| Known as | NSC-743769 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | PALO | “BACKGROUND: NEPA, an oral fixed combination of the NK1RA netupitant (300 mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50 mg), is the first fixed...” PMID 29722791 ↗ Jul 20182“This post-hoc analysis evaluated the efficacy of NEPA, a fixed combination of netupitant (NETU [NK1RA]) and palonosetron (PALO [5-HT3RA]) in BC patients from two phase III studies.” PMID 28285236 ↗ Mar 2017 “Palonosetron (PALO)” NCT00900757 ↗ |
| Known as | Palonocetron hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | Palonosetron (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | Palonosetron accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | Palonosetron HCl | “Palonosetron HCl Buccal Film 0.25 Mg” NCT04592198 ↗ |
| Known as | Palonosetron hospira | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | Palonosetron Hydrochloride | “Fosrolapitant and Palonosetron Hydrochloride for Injection: Intravenous drip for 1 hour (+10 minutes), once before each cycle of chemotherapy.” NCT07617246 ↗16“palonosetron hydrochloride injection: Drug for preventing nausea and vomiting caused by chemotherapy” NCT05509634 ↗ “Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist” NCT00967499 ↗ “Rolapitant Palonosetron (Rolapitant 218 mg and Palonosetron Hydrochloride 0.25 mg), IV;” NCT07442890 ↗ “Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution” NCT04592198 ↗ “Patients receive palonosetron hydrochloride IV on day 1.” NCT00903396 ↗ “Palonosetron hydrochloride IV injection” NCT05199818 ↗ “Netupitant/Palonosetron Hydrochloride” NCT07662200 ↗ “Drug: Palonosetron Hydrochloride” NCT01481831 ↗ “Drug: Palonosetron Hydrochloride” NCT03040726 ↗ “Drug: Palonosetron Hydrochloride” NCT05315999 ↗ |
| Known as | Palonosetron hydrochloride component of akynzeo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | palonosetron hydrochloride injection | “Palonosetron hydrochloride injection： 0.25 mg palonosetron in 5 mL (0.05 mg/mL) infusion time is 30 seconds (﹢5seconds)” NCT06427681 ↗1“fosaprepitant dimeglumine for injection+palonosetron hydrochloride injection+dexamethasone” NCT07692451 ↗ |
| Known as | Palonosetron injection | “Active Comparator: Drug：HR20013 placebo Drug: fosaprepitant dimeglumine for injection Drug：Palonosetron injection Drug: Dexamethasone” NCT07692451 ↗ |
| Known as | palonosetron(aloxi) | “palonosetron(aloxi)” NCT02532634 ↗ |
| Known as | Palonosetron, (3as, 3s)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | Posfrea | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Known as | RS-25259-197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1189679 ↗ |
| Action | Inhibit | “Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist” PMID 19135415 ↗ Jan 20091“Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL1189679 ↗ |
| Modality | Other / unclassified | “Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist” NCT00967499 ↗ |
| Route | Intravenous | “Patients were randomized to subcutaneous APF530 250 or 500 mg (granisetron 5 or 10 mg) or intravenous palonosetron 0.25 mg during cycle 1.” PMID 26921245 ↗ Feb 2016 |
| Target | HTR3A | “Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL1189679 ↗ |